
    
      The study is an open-label, dose escalation and expansion clinical trial to evaluate the
      safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors. The
      study will consist of two phases:

        -  A dose escalation phase - A 3+3 design will be used for this portion of the study.

        -  A dose expansion phase - Five cohorts will be evaluated in Dose Expansion. Cohort A will
           evaluate the MTD/RP2D in patients with advanced solid tumors. Cohort B and Cohort C will
           evaluate the MTD/RP2D in metastatic colorectal cancer patients. Cohort D and Cohort E
           will evaluate the MTD/RP2D in metastatic breast cancer patients.

      Study will be conducted in up to 9 sites in the US.
    
  